肺表面活性剂的药物（英语：Pulmonary surfactant (medication)）属于世界卫生组织基本药物标准清单范畴，是基础醫療系統最重要的药物之一。 根据拉普拉斯法则，因为肺泡被包裹在肺液体中 ...

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, is excited to announce ...

Novartis NVS announced that the European Commission (“EC”) has approved its breast cancer drug Kisqali (ribociclib) for a ...

The European Commission has cleared use of CDK4/6 inhibitor Kisqali (ribociclib) to reduce the risk of recurrence in patients ...

The study involved only Chinese patients, so would not be suitable for marketing applications in the US. It's worth noting, ...

The European Commission (EC) has granted approval to Novartis' Kisqali (ribociclib), plus an aromatase inhibitor to treat ...

RHHBY is set to acquire Poseida. MRK and AZN's late-stage studies for expanded use of new drugs meet their respective goals.

Lipopolysaccharide functions as a vaccine adjuvant but is considered too toxic for clinical use. The major structural element responsible for its toxicity and adjuvant effect is lipid A.

Oxford University researchers have made a significant step toward realizing a form of "biological electricity" that could be ...

If it’s challenging to lose weight despite making changes to your diet and increasing your physical activity, you may be wondering whether a prescription weight loss medication is right for you.

Novartis Kisqali receives European approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence: Basel Thursday, November 28, 2024, 09: ...

Aarti Surfactants Ltd., incorporated in the year 2018, is a Small Cap company (having a market cap of Rs 540.24 Crore) operating in Chemicals sector. Aarti Surfactants Ltd. key Products/Revenue ...